CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 133 enrolled
Drug / intervention
AGS-16C3F +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02639182
NCT02639182Phase 2Completed
CompareCT.gov

A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Astellas Pharma Global Development, Inc.·interventional·Posted Dec 24, 2015·Updated Nov 18, 2024

In Brief

A Phase 2 clinical trial evaluating AGS-16C3F and Axitinib for Metastatic Renal Cell Carcinoma. Completed, enrolled 133 participants across 26 sites in 2 countries.

Detailed Summary

The purpose of this study was to evaluate the progression free survival (PFS), based on investigator radiologic review, of AGS-16C3F compared to axitinib in subjects with metastatic renal cell carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 24, 2015
Enrollment StartMay 3, 2016
Primary CompletionOct 2, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 10.5 years ago

Interventions

AGS-16C3Fdrug

Intravenous (IV) infusion

Axitinibdrug

Oral